Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (6796)	4/10/1998 12:32:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Alien, I agree that we won't see any type of rapid short squeeze soon. I do think however that once the Viagra hype subsides and once Vivus gets the production numbers moving along with the opening of new markets the price will start moving. The short interest will certainly help upward momentum (not rapid squeezes) as time progresses with good news. Vivus needs to talk to the AOL PR department. Every time someone at AOL farts I see about 3 net news reports. Vivus should announce the following in timely press releases: 1. As soon as the FDA does it's final inspection of the new plant there should be an announcement. This will place the beaurocrats at the FDA in the fish bowl--the public can then all see just how efficiently our tax dollars are being spent. Hopefully it will intice the FDA to push it's paperwork a bit faster and cut down on the coffee breaks. 2. Any time MUSE gains regulatory acceptance in a new country, Vivus needs to announce. IMO in places where there are a lot of older men, I think some billboard advertising would be very helpful. Where I live (Southwest Florida) there is only one (non highway) main road running from Naples through Fort Myers and all the way North to Sarasota. The elderly people here are numerous and well off--most have good insurance coverage and probably can easily afford to pay for MUSE out of pocket if need be. Vivus needs to make more announcements in regards to their new product development to eliminate the "one drug" image.